Germ killing technology company Byotrol's share price received a boost after it said that it had its US patent application accepted.Byotrol, which applied for the patent in 2002, said the patent runs until 2022. Meanwhile, a Fortune 150 multinational company has paid Byotrol and its joint venture partner Byotrol Consumer Products (BCP) $250,000 for the right to enter into exclusive negotiations to license Byotrol's patented technology. The negotiations are scheduled to run for six months with an option to run for an extra three months, subject to further payments to Byotrol and BCP. The unnamed company is principally interested in Byotrol's technology in the fields of pre-saturated wipes and liquids for certain surface care markets, The negotiations specifically exclude all currently contracted areas of business. 'At this very early stage there is no guarantee that this particular agreement will lead to any formal supply agreements, but it is an important step forward for the company,' said David McRobbie, chief executive of Byotrol.